Establishing treatment benchmarks for mammography-screened breast cancer population based on a review of evidence-based clinical guidelines

Cancer

Volumn 112, Issue 9, 2008, Pages 1912-1922

  Delaney, Geoff ^a,b,d   Shafiq, Jesmin ^a   Chappell, Genevieve ^c   Barton, Michael ^a,b  

^a CENTRAL SYDNEY AREA HEALTH SERVICE   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c BreastScreen Victoria   (Australia)

^d LIVERPOOL HOSPITAL   (Australia)

Author keywords

Breast cancer; Cancer; Evidence based medicine; Mammography; Screening; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER SCREENING; EVIDENCE BASED PRACTICE; FEMALE; HUMAN; MAMMOGRAPHY; MASTECTOMY; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT INDICATION; BREAST TUMOR; EVIDENCE BASED MEDICINE; MIDDLE AGED; QUALITY CONTROL;

AGED; BENCHMARKING; BREAST NEOPLASMS; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MAMMOGRAPHY; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC;

EID: 42449086344     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23384     Document Type: Article

References (48)

1. National Institutes of Health. Breast Cancer Screening for Women Ages 40-49. NIH Consensus Statement Online 1997 Jan 21-23;15:1-35. Available from URL: http://consensus.nih. gov/1997/1997BreastCancerScreening103html.htm Accessed August 29, 2007.
2. Shapiro S, Venet W, Strax P, et al. Ten- to fourteen-year effect of screening on breast cancer mortality. J Natl Cancer Inst. 1982;69:349-355.
3. Roberts MM, Alexander FE, Anderson TJ, et al. Edinburgh trial of screening for breast cancer: mortality at 7 years. Lancet. 1990;335:241-246.
4. Miller AB, To T, Baines CJ, et al. The Canadian National Breast Screening Study-1: breast cancer mortality after 11 to 16 years of follow-up. A randomized screening trial of mammography in women age 40 to 49 years. Ann Intern Med. 2002;137:305-312.
5. Miller AB, Baines CJ, To T, et al. Canadian National Breast Screening Study: 2. Breast cancer detection and death rates among women aged 50 to 59 years. CMAJ. 1992;147:1477-1488.
6. Nystrom L, Rutqvist LE, Wall S, et al. Breast cancer screening with mammography: overview of Swedish randomised trials. Lancet. 1993;341:973-978.
7. Nystrom L, Andersson I, Bjurstam N, et al. Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet. 2002;359:909-919.
8. Veronesi U, Banfi A, Salvadori B, et al. Breast conservation is the treatment of choice in small breast cancer: long-term results of a randomized trial [see comments]. Eur J Cancer. 1990;26:668-670.
9. Blichert-Toft M, Rose C, Andersen JA, et al. Danish randomized trial comparing breast conservation therapy with mastectomy: 6 years of life-table analysis.Danish Breast Cancer Cooperative Group. J Natl Cancer Inst Monogr. 1992;19-25.
10. Ragaz J, Jackson SM, Le N, et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med. 1997;337:956-962.
11. Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med. 1997;337:949-955.
12. Sun J, Chapman J, Gordon R, et al. Survival from primary breast cancer after routine clinical use of mammography. Breast J. 2002;8:199-208.
13. Olivotto IA, Kan L, d'Yachkova Y, et al. Ten years of breast screening in the Screening Mammography Program of British Columbia, 1988-97. J Med Screen. 2000;7:152-159.
14. Ascunce N, del Moral A, Murillo A, et al. Early detection programme for breast cancer in Navarra, Spain. Eur J Cancer Prev. 1994;3(suppl 1):41-48.
15. BreastScreen Victoria. BreastScreen Victoria 2002 Annual Statistical Report. Melbourne: BreastScreen Victoria; 2002.
16. Vejborg I, Olsen AH, Jensen MB, et al. Early outcome of mammography screening in Copenhagen 1991-99. J Med Screen. 2002;9:115-119.
17. Freedman GM, Anderson PR, Goldstein LJ, et al. Routine mammography is associated with earlier stage disease and greater eligibility for breast conservation in breast carcinoma patients age 40 years and older. Cancer. 2003;98:918-925.
18. Delaney G, Barton B, Jacob S. Estimation of an optimal radiotherapy utilization rate for breast cancer: a review of the evidence. Cancer. 2003;98:1977-1986.
19. Delaney G, Barton M, Jacob S, Jalaludin B. A model for decision making for the use of radiotherapy in lung cancer. Lancet Oncol. 2003;4:120-128.
20. Delaney G, Barton M, Jacob S. Estimation of an optimal radiotherapy utilization rate for melanoma. A review of the evidence. Cancer. 2004;100:1293-1301.
21. Delaney G, Barton M, Jacob S. Estimation of an optimal radiotherapy utilization rate for gastrointestinal cancer: a review of the evidence. Cancer. 2004;101:657-670.
22. Delaney G, Jacob S, Barton M. Estimating the optimal external beam radiotherapy utilization rate for genitourinary malignancies. Cancer. 2005;103:462-473.
23. Delaney G, Jacob S, Barton M. Estimation of an optimal external beam radiotherapy utilization rate for head and neck carcinoma. Cancer. 2005;103:2216-2227.
24. Delaney G, Jacob S, Barton M. Estimation of an optimal radiotherapy utilization rate for gynecological cancer. Part I. Malignancies of the cervix, ovary, vagina and vulva. Cancer. 2004;101:671-681.
25. Delaney G, Jacob S, Barton M. Estimation of an optimal radiotherapy utilization rate for gynecological cancer. Part II. Carcinoma of the endometrium. Cancer. 2004;101: 682-692.
26. Featherstone C, Delaney G, Jacob S, Barton M. Estimating the optimal utilization rates of radiotherapy for hematological malignancies from a review of the evidence. Part I. Lymphoma. Cancer. 2005;103:383-392.
27. Featherstone C, Delaney G, Jacob S, Barton M. Estimating the optimal utilization rates of radiotherapy for hematological malignancies from a review of the evidence. Part II. Leukemia and myeloma. Cancer. 2005;103:393-401.
28. Delaney G, Jacob S, Barton M. Estimating the optimal radiotherapy utilization for cancer of the central nervous system, thyroid cancer and cancer of unknown primary origin from evidence-based clinical guidelines. Cancer. 2006; 106:453-465.
29. Delaney G, Jacob S, Featherstone C, Barton M. The role of radiotherapy in cancer treatment: Estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer. 2005;104:1129-1137.
30. National Health and Medical Research Council (NHMRC). Clinical Practice Guidelines for the Management of Early Breast Cancer. 2nd ed. Canberra: NHMRC; 2001.
31. National Health and Medical Research Council (NHMRC). Clinical Practice Guidelines for the Management of Advanced Breast Cancer: Prepared by the iSource National Breast Cancer Centre Advanced Breast Cancer Working Group. Canberra: NHMRC; 2001.
32. National Health and Medical Research Council (NHMRC). Guide to the Development, Implementation and Evaluation of Clinical Practice Guidelines (Appendix B, 56). Canberra: NHMRC; 1998.
33. TreeAge decision-analysis software [computer program]. Version 3.5. Williamstown, MA: TreeAge Software; 2003.
34. BreastScreen Victoria. BreastScreen Victoria 1992-2002: A Decade of Achievement. Melbourne: BreastScreen Victoria; 2002.
35. Australian Bureau of Statistics (ABS). Population by Age and Sex, Australian States and Territories. 3201.0. June 2005. Available from URL: http://www.ausstats.abs.gov.au/ ausstats/subscriber.nsf/0/ BBE2D9B6FD4EF8B6CA2570D800 1B8F97/$File/32010_jun%202005.pdf Accessed July 19, 2007.
36. Silverstein MJ, Buchanan C. Ductal carcinoma in situ: USC/Van Nuys Prognostic Index and the impact of margin status. Breast. 2003;12:457-471.
37. National Health and Medical Research Council (NHMRC0 National Breast Cancer Centre. Surgical Management of Breast Cancer in Australia. Sydney: NHMRC National Breast Cancer Centre; 1999.
38. National Breast Cancer Centre. 2003. The Clinical Management of Ductal Carcinoma In Situ, Lobular Carcinoma In Situ and Atypical Hyperplasia of the Breast. 1st ed. Camperdown, NSW: National Breast Cancer Centre; 2003.
39. National Cancer Institute. Breast Cancer (PDQ(®): Treatment. Available from URL: http://www.cancer.gov/cancertopics/ pdq/treatment/breast/ HealthProfessional/page7 Accessed August 30, 2007.
40. National Comprehensive Cancer Network. National Practice Guidelines in Oncology - Breast Cancer. Version 2.2007. Available from URL: http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf Accessed August 30, 2007.
41. Foroudi F, Tyldesley S, Walker H, Mackillop WJ. An evidence-based estimate of appropriate radiotherapy utilization rate for breast cancer. Int J Radiat Oncol Biol Phys. 2002;53:1240-1253.
42. Farrow DC, Hunt WC, Samet JM. Geographic variation in the treatment of localized breast cancer. N Engl J Med. 1992;326:1097-1101.
43. Locker GY, Sainsbury JR, Cuzick J;ATAC Trialists' Group. Breast surgery in the Arimidex, Tamoxifen Alone or in Combination' (ATAC) trial: American women are more likely than women from the United Kingdom to undergo mastectomy. Cancer. 2004;101:735-740.
44. Hiotis K, Ye W, Sposto R, et al. The importance of location in determining breast conservation rates. Am J Surg. 2005;190:18-22.
45. De Laurentis M, De Placido S, Bianco AP, Clark GM, Ravdin PM. A prognostic model that makes quantitative estimates of probability of relapse for breast cancer patients. Clin Cancer Res. 1999;5:4133-4139.
46. Early Breast Cancer Triallists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet. 1998;352:930-942.
47. Morrow M. Breast conserving therapy: who and why? J Surg Oncol. 2003;84:55-56.
48. Palda VA, Llewellyn-Thomas HA, Mackenzie RG, et al. Breast cancer patients' attitudes about rationing postlumpectomy radiation therapy: applicability of trade-off methods to policy-making. J Clin Oncol. 1997;15:3192-3200.